Area Poster - Oral Poster
Antiretroviral Therapy I
OP 1
Real-life Experience with Dolutegravir-Based Two-Drug Regimens
R. Pincino
OP 2
Comparison of efficacy and tolerability of Dolutegravir / Rilpivirine or Dolutegravir / Lamivudine in experienced HIV-1 positive patients switched from a three-drug regimen based on Non-Nucleoside Reverse Transcriptase Inhibitors in a single center in Italy
F. Lagi
OP 3
Efficacy and safety of switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in virologically-suppressed HIV patients (EBONY Study)
S. Cicalini
OP 4
Efficacy and tolerability of a switch to bictegravir/emtricitabine/tenofovir alafenamide in virally suppressed PLWH
D. Canetti
OP 5
Efficacy, safety and feasibility of a rapid antiretroviral therapy starting B/F/TAF in advanced hiv disease (Rainbow study)
M. Camici
OP 6
Effectiveness, safety and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people living with HIV (PLWH) in routine clinical practice: 6-month results of the Italian BICSTaR cohort
A. d'Arminio Monforte
Antiretroviral Therapy II
OP 43
Changes in serum inflammatory and immune activation markers associated with lamivudine/dolutegravir and tenofovir alafenamide/emtricitabine/bictegravir as initial antiretroviral treatment
L. Calza
OP 44
Cardiovascular risk and lipid profile after switching to TAF/FTC/RPV or TAF/FTC/EVG/cobi in people living with HIV and controlled plasma viremia
S. Rusconi
OP 45
Who could be eligible for long-acting antiretroviral treatment? A snapchat from Antiviral Response Cohort Analysis (ARCA) Italian cohort
A. De Vito
OP 46
HIV-DNA decay in ART-naïve patients starting dolutegravir plus lamivudine vs triple therapy
F. Lombardi
OP 47
Real-life impact of drug toxicity on dolutegravir tolerability: clinical practice data from a multicenter Italian cohort
G. Baldin
OP 48
Prevalence and incidence of multidrug resistance in the ARCA database, 2020 update
F. Incardona
Coinfections and Hepatitis
OP 19
Impact of polypharmacy and aging on the risk of multiple drug-drug interactions (DDIs) in HCV patients treated with pangenotypic direct-acting antivirals (pDAA)
N. Coppola
OP 20
HBeAg levels vary across the different phases of HBV infection, and can be predictive of therapeutic outcome in the setting of immunosuppression-driven HBV reactivation
L. Piermatteo
OP 21
HCV knowledge and awarness among injecting drug users in the direct acting antivirals era
A. Boschini
OP 22
A pilot intervention for HCV elimination among MSM in Rome: an update on more than 1200 screened individuals
P. Piselli
OP 23
Humoral response to mRNA SARS-CoV-2 vaccine in cirrhotic patients without prior exposure to the virus
C. Sorace
OP 24
Syphilis reinfection in people living with HIV (PLWH): a monocentric retrospective study
G. Tiecco
Comorbidities / Miscellaneous
OP 7
MARAND-X: clinical trial on the use of less neurotoxic antiretrovirals in HAND
A. Lazzaro
OP 8
Management of diabetes mellitus in people living with HIV and diabetes: a single-center experience
C. Resnati
OP 9
The interplay between resilience and health related quality of Life in PLWH during the COVID era: a comparison of a geriatric cohort with a cohort of PLWH younger than 65 years
G. Guaraldi
OP 10
Efficacy and Tolerability of Doravirine + Raltegravir combination regimen as therapy of switch in ART experienced PLWHIV: the DOR-INI experience
M. Poliseno
OP 11
Trends of polypharmacy and 2DR antiretroviral use: a 15-year observational matched-cohort study
S. Cantergiani
OP 12
Rapid, drug-resistance-driven, start of antiretroviral therapy: an open-label, prospective, proof-of-concept, clinical study (TWODAY Study)
N. Gianotti
Epidemiology / Social Sciences I
OP 31
SARS-CoV-2 evolutionary dynamics in the first phase of the epidemic in Italy
A. Lai
OP 32
Characterization of SARS-CoV-2 variants circulating in Central Italy by deep-sequencing of full-length S gene
M.C. Bellocchi
OP 33
Impact of COVID pandemic and anti-SARS-CoV-2 immunization on vaccination against sexually transmitted infections
R. Rossotti
OP 34
Influenza vaccine: knowledge and beliefs among adherent PLWH during the first seasonal campaign of the COVID-19 era
S. Storti
OP 35
Results of a SARS-CoV-2 worker screening in the Marche Nord companies to prevent virus infection in the workplace
A. Casabianca
OP 36
A mixed method of follow-up with total patient care provided continuum with saving of hospital checks during the COVID-19 pandemic
P. Fusco
Epidemiology / Social Sciences II
OP 37
HIV-related internalized stigma and patient health engagement (PHE) model in an Italian cohort of people living with HIV
V. Massaroni
OP 38
Talking about stigma and Hiv prevention, the artists' contribution
G. Dessì
OP 38
Talking about stigma and Hiv prevention, the artists' contribution
OP 39
A visual scale to evaluate the quality of life in PLWHA. Fourth-90, utopia or reality?
F. Paciosi
OP 40
Health-related quality of life (HRQoL) from HIV patients' perspective: comparison of patients-reported outcome (PRO) measures among people living with HIV (PLWH) and other chronic clinical conditions
C. Seguiti
OP 41
Using technology to support vulnerable PLWHIV at the time of coronavirus
S. Patrucco
OP 42
Impact of SARS-CoV-2 pandemic on quality of life in people with HIV
M. Fois
Epidemiology / Social Sciences III
OP 73
Pre-Exposure Prophylaxis (PrEP) though the SARS-CoV-2 pandemic period: the experience of the dedicated service of Tuscany Region in S.M.Annunziata Hospital, Florence
E. Salomoni
OP 74
PreP experience at Milano Checkpoint: promoting health and well-being through the integration of complementary skills
A. Bianchi
OP 75
Rapid tests in the pandemic: the "continuum of care" of Villa Maraini during the Covid-19 emergency
T. Di Giovanni
OP 76
Covid-19 in HIV/AIDS out-of-hospital facilities in Lombardy
L.A. Rancilio
OP 77
The COVID-19 pandemic impact on retention in care and viral suppression at the Infectious Diseases Unit of S. M. Annunziata Hospital, Florence: comparing 2019 and 2020 data
C. Costa
OP 78
Reaching 90-90-90 in the municipality of Kilamba Kiaxi, Luanda, Angola. The experience of PIPSA project
T. Baldoni
HIV & Covid I
OP 13
UV irradiation and SARS‐CoV‐2: a focus on UVA/UVB/UVC -inactivation on viral replication
S. Strizzi
OP 14
Determinants and characteristics of progressor and non progressor SARS COV-2 infected patients
P. ZuccalÃ
OP 15
Metabolic associated fatty liver disease is highly prevalent in the post-acute COVID syndrome
J. Milic
OP 16
Assessment of well-being, resilience and intrinsic capacity in patients with post-acute COVID-19 syndrome
T. Marchio
OP 17
Achieving virological control in pan-resistant HIV-1 infection
D. Canetti
OP 18
Resilience and frailty in people living with HIV during the COVID era: two complementary constructs associated with health-related quality of life
G. Guaraldi
HIV & Covid II
OP 49
Real life use of the anti-SARS CoV-2 monoclonal antibodies in the early phase of infection: planning, enrollment, administration and monitoring
C. Del Borgo
OP 50
Learning by doing: effects of monoclonal antibody treatment on the outcome of ambulatory patients with COVID-19
C. Leanza
OP 51
Efficacy, safety and virological clearance in course of treatment with anti-SARS-CoV-2 monoclonal antibodies in patients diagnosed with mild-moderate COVID-19
C. Falcinella
OP 52
Ex vivo efficacy of currently licensed anti-SARS-CoV-2 monoclonal antibodies
F. Dragoni
OP 53
Real-life use of remdesivir-containing regimens in Coronavirus Disease-2019: a retrospective case-control study
F. Cogliati Dezza
OP 54
SARS-CoV-2 infection Among Persons living with HIV
S.R. Bruno
Immunopathogenesis I
OP 25
Decreased neutralization of the B.1.525 (Nigerian) SARS-CoV-2 variant by sera of previously infected and uninfected vaccinated individuals
I. Vicenti
OP 26
Severity of COVID-19 patients predicted by serum sphingolipids signature
E. Torretta
OP 27
Expansion of myeloid derived suppressor cells contribute to platelet activation by L-Arginine deprivation during SARS-CoV-2 infection
A. Sacchi
OP 28
Cysteamine is an approved drug with antiviral and immunomodulatory properties promising for COVID-19 treatment
T. Alonzi
OP 29
High CD169 monocyte/lymphocyte ratio reflects the immuno-phenotyping disruption and predicts oxygen need in COVID-19 patients
M. Fanelli
OP 30
Effect of SARS-CoV-2 sequences on immune response in A549-ACE2 lung cells
G. Cappelletti
Immunopathogenesis II
OP 55
Increased rates of indeterminate QuantiFERON-TB Gold Plus assay in severe COVID-19 patients reflect an impaired interferon-gamma secretion and correlate with the profound reduction of T-lymphocyte subsets in peripheral blood
A. Imeneo
OP 56
Role of serum E-selectin as a biomarker of infection severity in Coronavirus Disease-19
E. Rando
OP 57
Effects of viremia and CD4 recovery on the gut “microbiome-immunity” axis in naïve HIV-1 patients undergoing ART therapy
G. Nannini
OP 58
Cytokine profile of COVID-19 patients with and without active tuberculosis
S. Villa
OP 59
Role of Tocilizumab in down regulating the concentration of sCD163 in a cohort of SARS-COV 2 infected patients with varying severity
A. Carraro
OP 60
Clinical and immunological characterization of SARS-CoV-2 infection in children
M. Stracuzzi
Immunopathogenesis III
OP 61
Binding and neutralizing antibodies to interferon (IFN) α/β and defective IFN transcriptional profile in COVID-19 patients
F. Frasca
OP 62
Plasma cytokine landscape reveals the importance of different molecular pathways in predicting COVID-19 severity and survival
L. Gibellini
OP 63
Pregnant women develop a specific immunological long-lived memory against SARS-CoV-2
C. Fenizia
OP 64
Role of Type-I and -II interferons in SARS-CoV-2 infection: convergent effect, different mechanisms
F. Limanaqi
OP 65
Persistence of humoral immune response after one year from COVID-19 diagnosis: evidence from a monocentric study
P. Saltini
OP 66
Immunogenicity and safety of two doses of BNT162b2 vaccine in very elderly subjects
M. Beltrami
Social Sciences / Miscellaneous
OP 67
Patient outreach strategy to enhance retention to care of HIV-positive adolescent and youths: experience from HIV high burden setting
F. Di Gennaro
OP 68
Knowledge of HIV and STIs: which are the most vulnerable populations? Results from a web-based survey in Italy
A. Colpani
OP 69
HIV and Adolescents. Evaluation of an HIV and STI prevention project for high school students
D. Zagato
OP 70
SARS-CoV-2 variants surveillace highlights local emergence of different genotypes
C. Veneziano
OP 71
Access to HIV testing before and after SARS-CoV-2 pandemic in Milan: comparison between a health-care setting and a community setting
L. Biasioli
OP 72
Characterization of PLWH with low-level viremia: results from the Italian ARCA cohort
M. Ranzenigo
Virology
OP 79
Molecular evidence of HIV-1 transmission in a criminal case in Italy
L. Fabeni
OP 80
Assessment of specific immunological response after administration of anti-meningococcal quadrivalent conjugate vaccine MENVEO® in a population with vertically-transmitted HIV infection
E. Longoni
OP 81
Regulation of m6A methylation as new therapeutic option against COVID-19
C. Zannella
OP 82
Characterization of humoral and cellular immune response after SARS-CoV-2 mRNA vaccine in HIV-1 infected patients
L. Santinelli
OP 83
Safety and tolerability of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine in a diverse cohort of people with HIV (PWH)
L. Ferrari
OP 84
Differences in response to mRNA BNT162b2 vaccine among a cohort of Health Care Workers (HCWs): insights into the potential of a booster dose
M. Allegrini
Poster
Audio